SGLT2 Inhibitors Cardiovascular and Safety Outcomes in Chronic Diseases
SGLT2 Inhibitors Cardiovascular and Safety Outcomes in Chronic Diseases by Citeline
Om Podcasten
Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.